Free Trial

Semper Paratus Acquisition (TVGN) Competitors

Semper Paratus Acquisition logo
$1.04 +0.01 (+0.48%)
As of 01:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TVGN vs. CRMD, OCS, GHRS, TNGX, MNMD, MAZE, NAGE, UPB, DAWN, and KALV

Should you be buying Semper Paratus Acquisition stock or one of its competitors? The main competitors of Semper Paratus Acquisition include CorMedix (CRMD), Oculis (OCS), GH Research (GHRS), Tango Therapeutics (TNGX), Mind Medicine (MindMed) (MNMD), Maze Therapeutics (MAZE), Niagen Bioscience (NAGE), Upstream Bio (UPB), Day One Biopharmaceuticals (DAWN), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

Semper Paratus Acquisition vs. Its Competitors

Semper Paratus Acquisition (NASDAQ:TVGN) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

34.2% of CorMedix shares are held by institutional investors. 73.2% of Semper Paratus Acquisition shares are held by company insiders. Comparatively, 5.3% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CorMedix has a net margin of 20.81% compared to Semper Paratus Acquisition's net margin of 0.00%. CorMedix's return on equity of 22.57% beat Semper Paratus Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Semper Paratus AcquisitionN/A N/A -934.56%
CorMedix 20.81%22.57%17.02%

In the previous week, Semper Paratus Acquisition had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Semper Paratus Acquisition and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.48 beat Semper Paratus Acquisition's score of 0.85 indicating that CorMedix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Semper Paratus Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CorMedix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Semper Paratus Acquisition has higher earnings, but lower revenue than CorMedix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Semper Paratus AcquisitionN/AN/A-$13.73MN/AN/A
CorMedix$82.55M9.71-$17.93M$0.2253.70

Semper Paratus Acquisition currently has a consensus target price of $10.00, indicating a potential upside of 856.94%. CorMedix has a consensus target price of $17.14, indicating a potential upside of 45.09%. Given Semper Paratus Acquisition's stronger consensus rating and higher probable upside, analysts plainly believe Semper Paratus Acquisition is more favorable than CorMedix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semper Paratus Acquisition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
CorMedix
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.88

Semper Paratus Acquisition has a beta of -0.73, meaning that its share price is 173% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.

Summary

CorMedix beats Semper Paratus Acquisition on 9 of the 14 factors compared between the two stocks.

Get Semper Paratus Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVGN vs. The Competition

MetricSemper Paratus AcquisitionMED IndustryMedical SectorNASDAQ Exchange
Market Cap$194.92M$3.07B$5.62B$9.56B
Dividend YieldN/A2.39%4.71%4.03%
P/E RatioN/A21.5927.9220.09
Price / SalesN/A206.57393.0867.83
Price / CashN/A42.5736.3258.75
Price / Book-11.618.298.385.82
Net Income-$13.73M-$55.06M$3.25B$259.10M
7 Day Performance-3.24%-2.18%-1.52%-2.35%
1 Month Performance-16.40%16.08%9.12%9.69%
1 Year Performance60.77%6.02%35.67%17.11%

Semper Paratus Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVGN
Semper Paratus Acquisition
4.014 of 5 stars
$1.05
+0.5%
$10.00
+856.9%
+55.2%$194.92MN/A0.003Upcoming Earnings
CRMD
CorMedix
2.7565 of 5 stars
$11.98
+4.3%
$17.14
+43.1%
+148.7%$779.30M$43.47M54.4630Positive News
OCS
Oculis
2.248 of 5 stars
$17.90
+1.1%
$35.33
+97.4%
+56.0%$773.26M$780K-6.782
GHRS
GH Research
1.6863 of 5 stars
$14.98
+3.3%
$32.00
+113.6%
+22.2%$754.41MN/A-18.9610
TNGX
Tango Therapeutics
1.8839 of 5 stars
$6.67
-2.2%
$10.50
+57.4%
-33.9%$739.25M$42.07M-5.4790News Coverage
Upcoming Earnings
Gap Up
MNMD
Mind Medicine (MindMed)
2.1802 of 5 stars
$9.68
-0.8%
$24.00
+147.9%
+0.4%$737.40MN/A-7.5040
MAZE
Maze Therapeutics
N/A$16.36
-2.7%
$25.60
+56.5%
N/A$736.67M$167.50M0.00121Lockup Expiration
Gap Up
NAGE
Niagen Bioscience
1.3013 of 5 stars
$9.69
+4.0%
$13.22
+36.4%
N/A$734.13M$99.60M57.00120
UPB
Upstream Bio
2.0404 of 5 stars
$14.34
+5.2%
$56.50
+294.0%
N/A$733.21M$2.37M0.0038Upcoming Earnings
High Trading Volume
DAWN
Day One Biopharmaceuticals
2.9268 of 5 stars
$7.10
-1.8%
$29.00
+308.5%
-54.5%$732.85M$131.16M-10.0060Positive News
Upcoming Earnings
KALV
KalVista Pharmaceuticals
3.9284 of 5 stars
$13.57
-6.9%
$26.29
+93.7%
-5.0%$728.33MN/A-3.68100

Related Companies and Tools


This page (NASDAQ:TVGN) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners